FINHUB Insights

IDXX · Q2 FY26 · Apr 1 – Jun 30, 2026

Idexx Laboratories Q2 FY26: where the revenue came from and where it went

Idexx Laboratories Q2 FY26: revenue $1.2B (+10% year over year). Net profit $0.34B. Largest cohort IDEXX VetLab consumables $0.43B. The whole income statement as a sankey diagram from the SEC filing.

Period
Apr 1 – Jun 30, 2026
Reported
Aug 4, 2026 10-Q
Sankey diagram of Idexx Laboratories's income statement for Q2 FY26: revenue of $1.22 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$1.22B +10% year over year
Gross profit$0.78B 64% margin
Operating profit$0.43B 35% margin
Net profit$0.34B 28% margin

The numbers

All figures in billions of U.S. dollars, for Q2 FY26 (period ends Jun 30, 2026).
ItemValueShare of revenueYear over year
Revenue 1.22 100% +10%
IDEXX VetLab consumables 0.43 35% +15%
Reference laboratory 0.41 33% +11%
Rapid assay products 0.10 8% +1%
Recurring 0.08 6% +11%
Other 0.06 5%
Water segment 0.06 5% +15%
capital - instruments 0.05 4% −19%
services & accessories 0.04 3% +3%
Cost of revenue−0.4436%
Gross profit0.7864% margin+1pp
R&D−0.075%+0pp
Sales & marketing−0.1714%+0pp
G&A−0.1210%+1pp
Operating profit0.4335% margin+1pp
Tax−0.08
Interest & other costs−0.01
Net profit0.3428%+1pp
Filing on EDGAR More quarters of IDXX

Source of the numbers: tables in the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.